Charles Schwab Investment Management Inc Zentalis Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 497,362 shares of ZNTL stock, worth $915,146. This represents 0.0% of its overall portfolio holdings.

Number of Shares

497,362

Previous 406,210 22.44%

Holding current value

$915,146

Previous $1.49 Million 1.14%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$2.7 - $4.03 $246,110 - $367,342	91,152 Added 22.44%	497,362 $1.51 Million
Q3 2024 Nov 12, 2024	SELL	$2.9 - $4.57 $180,388 - $284,267	-62,203 Reduced 13.28%	406,210 $1.49 Million
Q2 2024 Aug 12, 2024	BUY	$4.09 - $16.13 $51,026 - $201,237	12,476 Added 2.74%	468,413 $1.92 Million
Q1 2024 May 08, 2024	BUY	$10.83 - $16.49 $109,534 - $166,779	10,114 Added 2.27%	455,937 $7.19 Million
Q4 2023 Feb 06, 2024	BUY	$9.84 - $20.13 $36,988 - $75,668	3,759 Added 0.85%	445,823 $6.75 Million
Q3 2023 Nov 08, 2023	BUY	$19.63 - $28.29 $710,978 - $1.02 Million	36,219 Added 8.92%	442,064 $8.87 Million
Q2 2023 Aug 09, 2023	BUY	$17.41 - $30.05 $1.26 Million - $2.17 Million	72,277 Added 21.67%	405,845 $11.4 Million
Q1 2023 May 11, 2023	SELL	$16.14 - $24.94 $35,330 - $54,593	-2,189 Reduced 0.65%	333,568 $5.74 Million
Q4 2022 Feb 13, 2023	BUY	$18.07 - $25.6 $221,429 - $313,702	12,254 Added 3.79%	335,757 $6.76 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $59,880 - $93,920	2,960 Added 0.92%	323,503 $7.01 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $943,964 - $2.75 Million	52,706 Added 19.68%	320,543 $9.01 Million
Q1 2022 May 13, 2022	BUY	$41.58 - $80.89 $284,032 - $552,559	6,831 Added 2.62%	267,837 $12.4 Million
Q4 2021 Feb 11, 2022	BUY	$66.92 - $84.79 $565,875 - $716,984	8,456 Added 3.35%	261,006 $21.9 Million
Q3 2021 Nov 16, 2021	BUY	$46.83 - $73.5 $4.6 Million - $7.22 Million	98,286 Added 63.71%	252,550 $16.8 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $950,924 - $1.58 Million	25,419 Added 19.73%	154,264 $8.21 Million
Q1 2021 May 17, 2021	BUY	$35.69 - $52.72 $155,501 - $229,701	4,357 Added 3.5%	128,845 $5.59 Million
Q4 2020 Feb 16, 2021	BUY	$31.71 - $57.97 $1.2 Million - $2.19 Million	37,817 Added 43.63%	124,488 $6.47 Million
Q3 2020 Nov 13, 2020	BUY	$27.03 - $47.97 $564,007 - $1 Million	20,866 Added 31.71%	86,671 $2.83 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $1.53 Million - $3.61 Million	65,805 New	65,805 $3.16 Million

Others Institutions Holding ZNTL

# of Institutions

147

Shares Held

65.3M

Call Options Held

43.2K

Put Options Held

21.7K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $105M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Zentalis Pharmaceuticals, Inc. Transaction History